Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML

Author:

Löwenberg Bob1,Pabst Thomas2,Maertens Johan3,van Norden Yvette4,Biemond Bart J.5,Schouten Harry C.6,Spertini Olivier7,Vellenga Edo8,Graux Carlos9,Havelange Violaine10,de Greef Georgine E.1,de Weerdt Okke11,Legdeur Marie-Cecile J. C.12,Kuball Juergen13,Kooy Marinus van Marwijk14,Gjertsen Bjorn T.15,Jongen-Lavrencic Mojca1,van de Loosdrecht Arjan A.16,van Lammeren-Venema Daniëlle17,Hodossy Beata18,Breems Dimitri A.19,Chalandon Yves20,Passweg Jakob21,Valk Peter J. M.1,Manz Markus G.22,Ossenkoppele Gert J.16

Affiliation:

1. Department of Hematology, Erasmus University Medical Center (MC), Rotterdam, The Netherlands;

2. Inselspital, Bern, Switzerland;

3. Department of Hematology, University Hospital Gasthuisberg, Leuven, Belgium;

4. HOVON Data Center, Erasmus University MC Cancer Institute, Rotterdam, The Netherlands;

5. Department of Hematology, Academic Medical Center, Amsterdam, The Netherlands;

6. Department of Hematology, University Hospital, Maastricht, The Netherlands;

7. Department of Hematology, University Hospital, Lausanne, Switzerland;

8. Department of Hematology, University Medical Center, Groningen, The Netherlands;

9. UCL Namur (Godinne), Yvoir, Belgium;

10. Department of Hematology, Hôpital St. Luc, Brussels, Belgium;

11. St. Antonius Hospital, Nieuwegein, The Netherlands;

12. Medisch Spectrum Twente, Enschede, The Netherlands;

13. Department of Hematology, University Medical Center, Utrecht, The Netherlands;

14. Isala Hospital, Zwolle, The Netherlands;

15. Haukeland University Hospital, Bergen, Norway;

16. Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands;

17. Haga Hospital, The Hague, The Netherlands;

18. Hôpital Citadelle, Liège, Belgium;

19. Ziekenhuis Netwerk Antwerpen, Antwerp, Belgium;

20. Department of Hematology, University Hospital and University of Geneva, Geneva, Switzerland;

21. Department of Hematology, University Hospital, Basel, Switzerland; and

22. Department of Hematology, University Hospital, Zurich, Switzerland

Abstract

Key Points Clofarabine integrated in standard induction therapy for newly diagnosed AML reduces relapse probability but does not improve survival. Clofarabine improves survival in intermediate-risk AML categories ELN-1 and the AML genotype without NPM1 and without FLT3-ITD gene mutations.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3